HC Wainwright Reiterates “Buy” Rating for iTeos Therapeutics (NASDAQ:ITOS)

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $21.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 170.27% from the company’s current price.

Several other equities analysts have also weighed in on ITOS. Wells Fargo & Company reduced their price objective on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a research note on Thursday, December 19th. Wedbush reiterated an “outperform” rating and issued a $25.00 price target on shares of iTeos Therapeutics in a report on Friday, January 10th.

iTeos Therapeutics Stock Performance

ITOS opened at $7.77 on Thursday. iTeos Therapeutics has a 1 year low of $7.09 and a 1 year high of $18.75. The company’s 50 day simple moving average is $8.08 and its 200 day simple moving average is $11.64. The stock has a market capitalization of $283.84 million, a PE ratio of -2.47 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. As a group, sell-side analysts expect that iTeos Therapeutics will post -3.49 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Matthew Gall purchased 5,000 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was acquired at an average cost of $7.73 per share, with a total value of $38,650.00. Following the acquisition, the chief financial officer now owns 65,429 shares in the company, valued at approximately $505,766.17. This trade represents a 8.27 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 12.50% of the company’s stock.

Hedge Funds Weigh In On iTeos Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ITOS. Marquette Asset Management LLC acquired a new stake in shares of iTeos Therapeutics during the fourth quarter valued at about $122,000. JPMorgan Chase & Co. lifted its stake in shares of iTeos Therapeutics by 1.2% in the third quarter. JPMorgan Chase & Co. now owns 467,319 shares of the company’s stock worth $4,771,000 after acquiring an additional 5,368 shares in the last quarter. Virtu Financial LLC purchased a new position in iTeos Therapeutics in the third quarter valued at about $102,000. Geode Capital Management LLC grew its stake in iTeos Therapeutics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 640,350 shares of the company’s stock valued at $6,540,000 after purchasing an additional 20,092 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in iTeos Therapeutics during the 3rd quarter worth approximately $186,000. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.